3SBio Inc. (HKG: 1530) reported 2025 financial results with revenues soaring 94.3% year-over-year (YOY) to RMB 17.7 billion (USD 2.58 billion) and net profits skyrocketing 305.8% YOY to RMB 8.48 billion (USD 1.23 billion). The extraordinary growth was primarily fueled by licensing income from its landmark alliance with Pfizer for 707, a breakthrough PD-1/VEGF bispecific antibody (BsAb), in a deal valued at over USD 6 billion.
Eltrombopag olamine: Thrombopoietin receptor agonist for additional indications
Core Product Expansion
Recombinant Human Thrombopoietin: Approved for new indication – treatment of thrombocytopenia associated with chronic liver disease (CLDT) in patients planning surgical or diagnostic procedures
Market Impact: Expands addressable patient population and reinforces leadership in hematology therapeutics
Business Segment Performance
Segment
2025 Revenue
Growth Driver
Biological Products
RMB 8.006B
Core product portfolio expansion and new indications
Pfizer deal representing transformational partnership value
Corporate Development – Mandi Inc. Spin-off
Subsidiary: Mandi Inc. focusing on hair loss, dermatology, and body weight management
Strategic Action: Proposed separate listing on Hong Kong Stock Exchange
Rationale: Unlock shareholder value by separating high-growth consumer health assets from core biopharmaceutical business
Market Opportunity: Dermatology and weight management represent rapidly growing consumer health segments in China
Execution Timeline: Subject to regulatory approvals and market conditions
Strategic Implications & Market Outlook
Global Recognition: Pfizer partnership validates 3SBio’s bispecific antibody platform and establishes international credibility
Financial Transformation: One-time licensing income creates war chest for internal R&D investment and strategic acquisitions
Diversification Strategy: Spin-off of Mandi Inc. enables focused execution in both biopharmaceutical and consumer health markets
Competitive Positioning: PD-1/VEGF bispecific represents next-generation immuno-oncology approach with potential advantages over monospecific antibodies
Sustainable Growth: Strong underlying biological product sales (+10.3%) demonstrate robust core business fundamentals beyond partnership income
Forward‑Looking Statements This brief contains forward-looking statements regarding financial performance, regulatory timelines, partnership execution, and corporate development activities. Actual results may differ due to risks including market volatility, regulatory decisions, competitive dynamics, and capital market conditions affecting the proposed Mandi Inc. spin-off.-Fineline Info & Tech
By Fineline Cube 